ISG15 Antibody

What is ISG15 and why is it significant in immunological research?

ISG15 is an interferon-stimulated gene product that functions as a ubiquitin-like modifier. It has significant importance in immunology research due to its dual role: as a free protein acting as an extracellular cytokine promoting IFN-γ production, and through its conjugation to target proteins (ISGylation). ISG15 is strongly upregulated by interferons (especially type I IFN), pathogen infections, and cellular stresses that activate IFN production . Its mature form contains two ubiquitin-like domains with a molecular weight of approximately 17,145 Daltons and ends with the amino acid sequence 'LRLRGG', identical to mature ubiquitin . Research interest in ISG15 has intensified as it plays a key role in the innate immune response to viral infections and is involved in various immunological pathways.

How does ISG15 antibody selection differ based on experimental applications?

Selecting the appropriate ISG15 antibody depends critically on your experimental design. For Western Blotting (WB), unconjugated antibodies with high specificity are generally preferred, while immunohistochemistry (IHC) may require antibodies optimized for tissue penetration and minimal background staining . For immunofluorescence applications, antibodies may be either directly conjugated to fluorophores or used with secondary antibodies. The reactivity profile also varies significantly - some antibodies react only with human ISG15, while others recognize multiple species including mouse and monkey . Applications like FACS require antibodies with different properties than those used for ELISA. Always review validation data for your specific application, as an antibody performing well in WB may not necessarily work for IHC or immunoprecipitation.

What controls should be included when validating a new ISG15 antibody?

When validating a new ISG15 antibody, several essential controls must be included:

• Positive controls: Cell lines or tissues known to express ISG15, particularly those treated with type I interferons to upregulate ISG15 expression .

• Negative controls: Samples where ISG15 is absent or knocked down (siRNA or CRISPR-mediated).

• Isotype controls: Especially important for flow cytometry to control for non-specific binding.

• Blocking peptide competition: Using the immunizing peptide to confirm specificity.

• Cross-reactivity assessment: Testing against tissue samples from different species if the antibody claims cross-reactivity .

• Secondary antibody-only controls: To verify the absence of non-specific binding from secondary antibodies.

For quantitative applications, include a standard curve using recombinant ISG15 protein. It's also advisable to benchmark against a previously validated ISG15 antibody with established performance in your application of interest.

How can ISG15 antibodies distinguish between free ISG15 and ISGylated proteins?

Distinguishing between free ISG15 and ISGylated proteins represents a significant challenge in research. Most commercial antibodies detect both forms, which can complicate interpretation. For targeted detection:

• Domain-specific antibodies: Some antibodies target specific epitopes that may be partially masked during conjugation.

• Size fractionation techniques: Free ISG15 (17.9 kDa) can be distinguished from ISGylated proteins (typically >30 kDa) using gradient gels and Western blotting .

• Combined immunoprecipitation approach: Sequential immunoprecipitation using antibodies against ISG15 and the suspected target protein.

• Denaturing conditions: Harsh denaturing conditions can disrupt non-covalent interactions while preserving the covalent ISG15-protein bonds.

When studying ISGylation, researchers should additionally consider using antibodies against specific ISGylated targets (such as IFIT1, MX1/MxA, PPM1B, UBE2L6, or UBA7) in parallel with anti-ISG15 antibodies . This combinatorial approach provides greater confidence in distinguishing the conjugated forms from free ISG15.

What are the challenges of interpreting ISG15 expression in clinical samples for disease biomarker studies?

Interpreting ISG15 expression in clinical samples presents several methodological challenges:

• Baseline variation: ISG15 expression levels vary considerably between individuals, necessitating appropriate normalization strategies.

• Induction dynamics: As an interferon-stimulated gene, ISG15 expression fluctuates with infection status and inflammatory conditions.

• Tissue-specific expression patterns: Recent studies show differential expression profiles in disease states, with particularly strong perivascular and lymphocyte localization in dermatomyositis patients .

• Correlation with immune cell populations: ISG15 expression correlates negatively with resting dendritic cells, M0 macrophages, activated and resting mast cells, plasma cells, naive CD4 T cells, CD8 T cells, and naive B cells, while showing positive correlation with M1 macrophages, monocytes, and resting memory CD4 T cells .

• Technical variability: Different antibodies can yield varying results due to epitope specificity differences.

How do post-translational modifications affect ISG15 antibody epitope recognition?

Post-translational modifications (PTMs) can significantly impact ISG15 antibody epitope recognition in ways that may confound experimental results:

• Conformational changes: PTMs may alter protein folding, potentially masking or exposing epitopes recognized by certain antibodies.

• Direct epitope modification: Phosphorylation, acetylation, or other modifications at or near antibody recognition sites can directly prevent antibody binding.

• ISGylation cascade interference: Modifications affecting the E1-E2-E3 enzyme cascade may alter the pattern of ISGylated proteins detected by anti-ISG15 antibodies.

• Species-specific modifications: The relatively low cross-species conservation of ISG15 (ranging from 98% between chimpanzee and human to 42% between opossum and human) suggests different post-translational regulation across species .

When selecting antibodies for experiments where PTMs may be relevant, researchers should verify whether the antibody has been validated under conditions where these modifications are present. Consider using multiple antibodies targeting different epitopes to provide a more complete picture of ISG15 status in your experimental system.

What are the optimal protocols for detecting ISGylated proteins using ISG15 antibodies?

Detection of ISGylated proteins requires careful experimental design. The following optimized protocol incorporates key methodological considerations:

• Sample preparation:

  • Treat cells with type I interferons (1000 U/ml IFN-α for 24h) to increase ISGylation

  • Include protease inhibitors AND deISGylase inhibitors (e.g., NEM) during lysis

  • Use denaturing conditions (8M urea buffer) to disrupt non-covalent interactions

• Enrichment strategies:

  • Immunoprecipitate with anti-ISG15 antibodies (select those validated for IP)

  • Consider tandem affinity purification for higher purity

  • Employ size-exclusion chromatography to separate free and conjugated forms

• Western blotting optimization:

  • Use gradient gels (4-15%) to resolve the wide molecular weight range of ISGylated proteins

  • Transfer larger proteins using lower methanol concentration and longer transfer times

  • Block with 5% BSA rather than milk (which contains bioactive proteins)

  • Probe with antibodies demonstrated to recognize the conjugated form

• Controls:

  • Include USP18 overexpression samples (reduces ISGylation)

  • Use UBE1L knockout cells as negative controls

  • Compare with and without interferon stimulation

This comprehensive approach enhances specificity and sensitivity when studying the ISG15 conjugation system in various experimental contexts.

How can researchers accurately quantify ISG15 expression levels across different sample types?

Accurate quantification of ISG15 across diverse sample types requires a multi-modal approach:

• Protein-level quantification:

  • Western blotting: Use recombinant ISG15 standards (5-100 ng range) for calibration curves

  • ELISA: Commercial kits with detection limits ~15-30 pg/ml provide higher throughput

  • Capillary electrophoresis: Offers superior resolution for distinguishing free vs. conjugated forms

• mRNA-level quantification:

  • RT-qPCR: Design primers spanning exon junctions to prevent genomic DNA amplification

  • Digital PCR: Provides absolute quantification without standard curves

  • RNA-seq: Offers contextual information on related pathway components

• Standardization across sample types:

  • Tissue samples: Normalize to total protein and tissue area

  • Cell lines: Account for cell number and type-specific baseline expression

  • Biological fluids: Consider concentration steps for low-abundance detection

• Cross-platform validation:

  • Compare protein vs. mRNA levels to identify post-transcriptional regulation

  • Validate with at least two independent techniques

  • Include spike-in controls for recovery efficiency assessment

What is the recommended workflow for studying ISG15's role in viral infection models?

The optimal workflow for investigating ISG15's role in viral infection models involves multiple complementary approaches:

• Experimental setup and controls:

  • Compare wild-type, ISG15 knockout, and UBE1L knockout models

  • Include systems where ISG15 is overexpressed

  • Design time-course experiments (pre-infection, early, and late stages)

• Infection protocols:

  • Standardize viral doses using plaque-forming units or TCID50

  • Account for cell-type tropism differences in virus replication

  • Monitor both viral replication and cell viability parameters

• ISG15 functionality assessment:

  • Track free vs. conjugated ISG15 using appropriate antibodies

  • Monitor key ISGylated targets like IFIH1/MDA5, which promotes oligomerization and triggers activation of innate immunity against various viruses

  • Assess disruption of viral budding in HIV-1 and Ebola virus models through ISG15's interaction with viral components and host factors

• Mechanistic investigation:

  • Examine ISG15's impact on viral protein stability

  • Assess interference with ubiquitination pathways

  • Evaluate effects on immune signaling cascades

• Downstream analysis:

  • Measure cytokine profiles, especially IFN-γ production

  • Perform transcriptome analysis of host response genes

  • Consider proteomics to identify novel ISGylation targets

This comprehensive workflow enables researchers to dissect both ISGylation-dependent and independent mechanisms by which ISG15 restricts viral replication across different viral families.

How should researchers interpret contradictory results between different ISG15 antibodies?

Contradictory results between different ISG15 antibodies occur frequently and require systematic analytical approaches:

• Epitope mapping analysis:

  • Compare the immunogen sequences used to generate each antibody

  • Assess whether antibodies target the N-terminal domain, C-terminal domain, or linker region

  • Determine if epitopes might be masked in specific protein conformations

• Validation strategy review:

  • Examine validation methods employed for each antibody (WB, IHC, IF)

  • Check if validation was performed in relevant tissue/cell types

  • Verify antibody performance in ISG15 knockout or knockdown models

• Technical optimization:

  • Test different fixation methods for IHC/IF applications

  • Adjust antibody concentrations and incubation conditions

  • Evaluate blocking reagents for reduction of non-specific binding

• Reconciliation approaches:

  • Employ multiple antibodies targeting different epitopes

  • Complement antibody-based detection with genetic approaches

  • Use mass spectrometry as an antibody-independent validation method

When publishing, explicitly report which antibody clone was used, at what concentration, and under what conditions, as these factors significantly influence experimental outcomes. When faced with contradictory results, prioritize data from antibodies with the most extensive validation in your specific experimental system.

What statistical considerations are important when analyzing ISG15 expression in disease biomarker studies?

Rigorous statistical approaches are essential when evaluating ISG15 as a disease biomarker:

• Power analysis and sample sizing:

  • Based on the anticipated effect size between disease and control groups

  • Consider biological variability of ISG15 expression

  • Account for technical variability between antibody lots and testing centers

• Appropriate control selection:

  • Match for age, sex, ethnicity, and treatment history

  • Include disease mimics to test specificity (e.g., other inflammatory conditions)

  • Consider longitudinal sampling to address temporal variability

• Advanced statistical methods:

  • Multivariate analysis to control for confounding factors

  • ROC curve analysis with confidence intervals (as seen in the dermatomyositis study with AUC=0.950, 95% CI: 0.775-1.000)

  • Machine learning approaches for complex pattern recognition

• Reporting standards:

  • Document all statistical tests and adjustments for multiple comparisons

  • Report both raw and normalized data

  • Include measures of central tendency and dispersion

• Validation cohorts:

  • Use independent patient populations

  • Implement cross-validation strategies

  • Consider multi-center validation for clinical applicability

How can researchers differentiate between the direct effects of ISG15 and broader interferon-induced responses?

Distinguishing ISG15-specific effects from general interferon responses requires sophisticated experimental designs:

• Genetic approach:

  • Compare ISG15 knockout to wild-type cells under interferon stimulation

  • Use UBE1L knockout to specifically impair ISGylation while preserving free ISG15

  • Employ siRNA-mediated knockdown with careful control selection

• Temporal dissection:

  • Analyze early vs. late interferon responses

  • Track the kinetics of ISG15 induction relative to other interferon-stimulated genes

  • Use pulse-chase experiments to monitor protein modification dynamics

• Pathway-specific interventions:

  • Apply specific inhibitors of interferon signaling components

  • Target ISG15 conjugation enzymes (E1-E2-E3 cascade)

  • Modulate deconjugation through USP18 manipulation

• Rescue experiments:

  • Reintroduce wild-type or mutant ISG15 into knockout backgrounds

  • Compare free ISG15 vs. conjugation-competent forms

  • Assess complementation with other interferon-stimulated genes

• Protein-protein interaction analysis:

  • Identify direct ISG15 binding partners distinct from other interferon-induced proteins

  • Map interaction networks using proximity labeling techniques

  • Validate functional relationships through mutagenesis

This systematic approach helps delineate the specific contribution of ISG15 within the complex network of interferon-mediated immune responses across different cellular contexts and disease models.

What are the most common pitfalls when using ISG15 antibodies, and how can they be avoided?

Researchers frequently encounter several pitfalls when working with ISG15 antibodies that can be systematically addressed:

• Non-specific binding issues:

  • Problem: Background bands in Western blots, particularly around 25-35 kDa range

  • Solution: Increase blocking time (5% BSA for 2+ hours), use higher antibody dilutions, and include detergents like 0.1% Tween-20 in washing steps

• Inconsistent detection of ISGylated proteins:

  • Problem: Variable detection of high molecular weight conjugates

  • Solution: Ensure complete denaturation (95°C for 10 minutes in SDS sample buffer), optimize gel percentage for target size range, and use PVDF membranes for better protein retention

• Fixation-sensitive epitopes in IHC/IF:

  • Problem: Some epitopes are masked by certain fixatives

  • Solution: Compare paraformaldehyde, methanol, and acetone fixation; consider antigen retrieval methods (citrate buffer pH 6.0 works well for many ISG15 epitopes)

• Species cross-reactivity limitations:

  • Problem: Unexpected lack of reactivity in non-human samples

  • Solution: Verify species cross-reactivity claims with validated positive controls; consider the relatively low cross-species conservation of ISG15 (as low as 42% between some mammals)

• Lot-to-lot variability:

  • Problem: Performance differences between antibody batches

  • Solution: Reserve sufficient antibody for critical experiments, validate each new lot against previous ones, and maintain detailed records of performance metrics

By anticipating these common issues and implementing preventative measures, researchers can substantially improve reliability and reproducibility in ISG15-focused experiments.

How do ISG15 antibody applications differ across various disease models beyond viral infections?

ISG15 antibodies have emerged as valuable tools across diverse disease contexts beyond viral infections:

• Autoimmune diseases:

  • In dermatomyositis, IHC with ISG15 antibodies reveals distinctive perivascular and lymphocyte-associated expression patterns that distinguish it from other inflammatory conditions

  • ROC analysis demonstrated ISG15's excellent potential as a diagnostic biomarker with an AUC of 0.950

• Cancer research applications:

  • ISG15 antibodies help characterize interferon response signatures in tumors

  • Different patterns of free versus conjugated ISG15 correlate with cancer progression and treatment response

  • IHC applications allow spatial characterization of ISG15 expression in tumor microenvironments

• Neurodegenerative disorders:

  • Emerging evidence suggests ISG15 involvement in neuroinflammatory processes

  • Antibodies enable detection of region-specific ISG15 upregulation in brain tissues

  • Co-localization studies with neuronal and glial markers provide insights into cell-specific responses

• Metabolic disease models:

  • ISG15 antibodies facilitate investigation of interferon-related inflammation in adipose tissue

  • Changes in ISGylation profiles detected by anti-ISG15 antibodies correlate with insulin resistance markers

Each disease context demands specific optimization of antibody selection, tissue preparation protocols, and analytical approaches to maximize informative outcomes while minimizing technical artifacts.

What emerging technologies are enhancing ISG15 antibody applications in research?

Cutting-edge technologies are revolutionizing how researchers utilize ISG15 antibodies:

• Single-cell analysis platforms:

  • Single-cell Western blotting now enables detection of ISG15 expression heterogeneity within populations

  • Mass cytometry with metal-conjugated ISG15 antibodies allows high-dimensional analysis alongside dozens of other markers

  • Imaging mass cytometry provides spatial context to single-cell ISG15 expression data

• Advanced microscopy techniques:

  • Super-resolution microscopy reveals subcellular localization patterns previously undetectable

  • Live-cell imaging with fluorescently tagged nanobodies against ISG15 enables temporal studies of expression dynamics

  • Correlative light and electron microscopy links ISG15 localization to ultrastructural features

• Proteomics integration:

  • Antibody-based enrichment coupled with mass spectrometry identifies novel ISGylation targets

  • Proximity labeling methods combined with ISG15 antibodies map the "ISGylome" in different cellular compartments

  • Cross-linking mass spectrometry reveals structural insights into ISG15-target interactions

• Spatial transcriptomics correlation:

  • Combining ISG15 IHC with spatial transcriptomics provides multi-omics insights

  • Digital spatial profiling technologies enable quantitative spatial analysis of ISG15 alongside hundreds of other proteins

These technological advances are expanding the scope and resolution of ISG15 research, enabling more comprehensive understanding of its functions across biological systems and disease states.